Australian melanoma experts share latest breakthroughs with world's best oncologists
6 June 2018
Research advancements and developments in melanoma treatment have seen advances in survival rates for melanoma patients over the last five years. Experts from Melanoma Institute Australia shared recent findings at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
The ASCO Annual Meeting brought together some 40,000 oncologists from around the world to discuss new therapies and treatment modalities.
A feature at ASCO was a poster presentation on an international study where MIA made a significant contribution, looking at potential mechanisms of response and resistance to anti-PD1 ipilimumab. Immune checkpoint, a regulator of the immune system, forms a blockade that improves the survival of patients with metastatic melanoma. But despite recent advances some patients just don’t respond to immunotherapy and the lack of accurate predictors of response of progression remains a clinical problem. MIA recognised this and sought to investigate by assessing the profiles of 141 melanoma biopsies. Patients were treated with anti-PD1 monotherapy or anti-PD1 + ipilimumab immunotherapy.
Results demonstrated that combinations of novel drug targets may provide clinical benefits in non-responding patients with high tumour-infiltrating lymphocytes (TILS).